Published in J Med Chem on February 11, 2010
Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chem Biol (2011) 2.06
Rejuvenating sirtuins: the rise of a new family of cancer drug targets. Curr Pharm Des (2013) 1.01
Sirtuin inhibitors as anticancer agents. Future Med Chem (2014) 0.98
Metabolism as a key to histone deacetylase inhibition. Crit Rev Biochem Mol Biol (2011) 0.95
3-(N-arylsulfamoyl)benzamides, inhibitors of human sirtuin type 2 (SIRT2). Bioorg Med Chem Lett (2012) 0.85
Sirtuin modulators. Handb Exp Pharmacol (2011) 0.84
Design of a novel nucleoside analog as potent inhibitor of the NAD dependent deacetylase, SIRT2. Syst Synth Biol (2011) 0.77
Ligand-based virtual screening and inductive learning for identification of SIRT1 inhibitors in natural products. Sci Rep (2016) 0.75
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenetics (2010) 2.26
SIRT1 regulates HIV transcription via Tat deacetylation. PLoS Biol (2005) 2.24
Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chem Biol (2011) 2.06
PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica (2010) 1.83
Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme. Chem Biol (2012) 1.82
Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Mol Cancer Ther (2009) 1.66
The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors. ChemMedChem (2009) 1.64
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS One (2009) 1.55
The nephronophthisis gene product NPHP2/Inversin interacts with Aurora A and interferes with HDAC6-mediated cilia disassembly. Nephrol Dial Transplant (2013) 1.47
Structure-activity studies on splitomicin derivatives as sirtuin inhibitors and computational prediction of binding mode. J Med Chem (2008) 1.31
Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors. Radiat Res (2004) 1.26
Subtype selective substrates for histone deacetylases. J Med Chem (2004) 1.25
Induction of human gamma globin gene expression by histone deacetylase inhibitors. Blood (2003) 1.23
Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem (2002) 1.23
Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family. Bioorg Med Chem (2011) 1.23
Structure-activity studies on suramin analogues as inhibitors of NAD+-dependent histone deacetylases (sirtuins). ChemMedChem (2007) 1.19
Activation, regulation, and inhibition of DYRK1A. FEBS J (2010) 1.18
Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor. Int J Cancer (2012) 1.18
Characterization of novel inhibitors of histone acetyltransferases. Mol Cancer Ther (2007) 1.17
4-Acyl pyrroles: mimicking acetylated lysines in histone code reading. Angew Chem Int Ed Engl (2013) 1.16
Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. Int J Cancer (2007) 1.16
Target-based approach to inhibitors of histone arginine methyltransferases. J Med Chem (2007) 1.16
Cancer treatment of the future: inhibitors of histone methyltransferases. Int J Biochem Cell Biol (2008) 1.14
Diminished sensitivity of chronic lymphocytic leukemia cells to ABT-737 and ABT-263 due to albumin binding in blood. Clin Cancer Res (2010) 1.12
Inhibitors of NAD+ dependent histone deacetylases (sirtuins). Curr Pharm Des (2008) 1.11
Destabilization of ERBB2 transcripts by targeting 3' untranslated region messenger RNA associated HuR and histone deacetylase-6. Mol Cancer Res (2008) 1.11
A novel arginine methyltransferase inhibitor with cellular activity. Bioorg Med Chem Lett (2007) 1.09
A convenient cellular assay for the identification of the molecular target of ergosterol biosynthesis inhibitors and quantification of their effects on total ergosterol biosynthesis. Steroids (2013) 1.09
New lysine methyltransferase drug targets in cancer. Nat Biotechnol (2012) 1.08
The potential of anti-malarial compounds derived from African medicinal plants, part I: a pharmacological evaluation of alkaloids and terpenoids. Malar J (2013) 1.07
Identification of selective inhibitors of NAD+-dependent deacetylases using phenotypic screens in yeast. J Biol Chem (2003) 1.06
Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition. J Med Chem (2006) 1.06
A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2. J Exp Med (2012) 1.05
CamMedNP: building the Cameroonian 3D structural natural products database for virtual screening. BMC Complement Altern Med (2013) 1.05
Mild hyperthermia triggered doxorubicin release from optimized stealth thermosensitive liposomes improves intratumoral drug delivery and efficacy. J Control Release (2013) 1.05
Arginine methylation of the B cell antigen receptor promotes differentiation. J Exp Med (2010) 1.02
Degradation of tropoelastin by matrix metalloproteinases--cleavage site specificities and release of matrikines. FEBS J (2010) 1.02
NAD(+) -dependent histone deacetylases (sirtuins) as novel therapeutic targets. Med Res Rev (2010) 1.02
N-(omega-(4-(2-methoxyphenyl)piperazin-1-yl)alkyl)carboxamides as dopamine D2 and D3 receptor ligands. J Med Chem (2003) 1.01
In vitro assays for the determination of histone deacetylase activity. Methods (2005) 1.00
Thiobarbiturates as sirtuin inhibitors: virtual screening, free-energy calculations, and biological testing. ChemMedChem (2008) 0.99
Comparative action of cobalt carbonyl complexes on cancer cells using human tumor xenografts. Anticancer Res (2002) 0.99
Atypical antipsychotics alter cholesterol and fatty acid metabolism in vitro. J Lipid Res (2012) 0.98
Hydroxamide derivatives of short-chain fatty acids are potent inducers of human fetal globin gene expression. Exp Hematol (2003) 0.98
Small molecule inhibitors of histone acetyltransferases as epigenetic tools and drug candidates. Arch Pharm (Weinheim) (2011) 0.98
Structural basis for the inhibition of histone deacetylase 8 (HDAC8), a key epigenetic player in the blood fluke Schistosoma mansoni. PLoS Pathog (2013) 0.97
Histone deacetylase inhibitors that target tubulin. Cancer Lett (2009) 0.97
The role of NAD+ dependent histone deacetylases (sirtuins) in ageing. Curr Drug Targets (2006) 0.97
Molecular dynamics simulations of bovine rhodopsin: influence of protonation states and different membrane-mimicking environments. J Mol Model (2005) 0.96
Determination of drug-serum protein interactions via fluorescence polarization measurements. Anal Bioanal Chem (2007) 0.95
Structural and synthetic investigations of tanikolide dimer, a SIRT2 selective inhibitor, and tanikolide seco-acid from the Madagascar marine cyanobacterium Lyngbya majuscula. J Org Chem (2009) 0.95
The ergot alkaloid gene cluster: functional analyses and evolutionary aspects. Phytochemistry (2009) 0.95
Phenylalanine-containing hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs). Bioorg Med Chem (2007) 0.95
Functional role and therapeutic potential of the pim-1 kinase in colon carcinoma. Neoplasia (2013) 0.94
In vivo application of histone deacetylase inhibitor trichostatin-a impairs murine male meiosis. J Androl (2007) 0.93
Acyl derivatives of p-aminosulfonamides and dapsone as new inhibitors of the arginine methyltransferase hPRMT1. Bioorg Med Chem (2011) 0.93
Azasteroids as antifungals. Steroids (2003) 0.92
Generation of a homology model of the human histamine H(3) receptor for ligand docking and pharmacophore-based screening. J Comput Aided Mol Des (2007) 0.92
Virtual screening and biological characterization of novel histone arginine methyltransferase PRMT1 inhibitors. ChemMedChem (2009) 0.91
The potential of anti-malarial compounds derived from African medicinal plants, part II: a pharmacological evaluation of non-alkaloids and non-terpenoids. Malar J (2014) 0.91
7,8-dichloro-1-oxo-β-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes. J Med Chem (2012) 0.90
AfroDb: a select highly potent and diverse natural product library from African medicinal plants. PLoS One (2013) 0.90
Homology modeling and molecular dynamics simulations of Dengue virus NS2B/NS3 protease: insight into molecular interaction. J Mol Recognit (2010) 0.90
Synthesis and Biological Evaluation of Novel Alkyl-Imidazolyl Carbinols and their Esters: Potent Antimycotics. Sci Pharm (2013) 0.90
Posaconazole therapeutic drug monitoring in the real-life setting: a single-center experience and review of the literature. Pharmacotherapy (2013) 0.90
Pyridylalanine-containing hydroxamic acids as selective HDAC6 inhibitors. ChemMedChem (2009) 0.90
The role of histone demethylases in cancer therapy. Mol Oncol (2012) 0.90
Nonisotopic substrate for assaying both human zinc and NAD+-dependent histone deacetylases. Anal Biochem (2003) 0.89
Amino acids important for ligand specificity of the human constitutive androstane receptor. J Biol Chem (2004) 0.89
Mechanism of dual specificity kinase activity of DYRK1A. FEBS J (2013) 0.89
A bioluminogenic HDAC activity assay: validation and screening. J Biomol Screen (2011) 0.89
Cameroonian medicinal plants: a bioactivity versus ethnobotanical survey and chemotaxonomic classification. BMC Complement Altern Med (2013) 0.89
Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based method. Antimicrob Agents Chemother (2010) 0.89
Schistosoma mansoni Sirtuins: characterization and potential as chemotherapeutic targets. PLoS Negl Trop Dis (2013) 0.88